CSPC Pharmaceutical Group Limited (1093.HK)
HKSE - HKSE Delayed Price. Currency in HKD
Add to watchlist
As of 09:47AM HKT. Market open.
| Previous Close | 5.860 |
| Open | 5.790 |
| Bid | 5.680 x 0 |
| Ask | 5.690 x 0 |
| Day's Range | 5.650 - 5.810 |
| 52 Week Range | 5.200 - 8.260 |
| Volume | |
| Avg. Volume | 40,144,403 |
| Market Cap | 67.778B |
| Beta (5Y Monthly) | 0.72 |
| PE Ratio (TTM) | 10.54 |
| EPS (TTM) | 0.540 |
| Earnings Date | May 23, 2024 - May 27, 2024 |
| Forward Dividend & Yield | 0.28 (4.78%) |
| Ex-Dividend Date | May 31, 2024 |
| 1y Target Est | 9.67 |
- Reuters
UPDATE 1-China's CSPC Pharma partners with Pfizer for oral COVID treatment
Chinese drug maker CSPC Pharmaceutical Group said on Thursday it signed a strategic partnership with Pfizer to launch a local brand of an oral COVID-19 treatment, in an attempt to improve the access for treatment in China. The combination of Nirmatrelvir and Ritonavir sold under the brand name Paxlovid, an oral small molecule developed by pharmaceutical company Pfizer, is used to treat patients suffering from mild to moderate COVID-19 symptoms and who are at the risk of disease progression. China, whose home-grown vaccines are seen as less effective than the Moderna and Pfizer-BioNTech mRNA shots, has been racing to develop vaccines using messenger RNA (mRNA) technology since early 2020.
© 2024 Yahoo. All rights reserved.